Curtisen Fails Prostate Cancer Patients

Curtisen Fails Prostate Cancer Patients

Back in October 2015, OncoGenx announced a phase 3 trial designed to evaluate whether the investigational treatment custirsen, when combined with cabazitaxel, improves survival in men with metastatic castrate-resistant prostate cancer.

Read More

ADT and Black Men

ADT and Black Men

ADT is frequently combined with radiation therapy for the treatment of men with intermediate- or high-risk prostate cancer. No evidence suggests that this treatment platform benefits patients with low- or favorable-risk disease.

Read More

Is There A Blueprint For Prostate Cancer?

Is There A Blueprint For Prostate Cancer?

Cancer researchers have applied a comprehensive set of analytical tools to lethal cases of metastatic prostate cancer, yielding a detailed map of the complex networks of interactions among genes and proteins that enable prostate cancer cells to proliferate and evade treatment.

Read More

Combating High Risk Prostate Cancer

Combating High Risk Prostate Cancer

Men with very high-risk prostate cancer, who are treated at hospitals with a high proportion of administered radical local treatment (radiotherapy or prostatectomy), only have half of the mortality risk of men who are treated at hospitals with the lowest proportion.

Read More